According to AVEO Oncology 's latest financial reports the company's current revenue (TTM) is $94.31 M. In 2021 the company made a revenue of $42.29 M an increase over the years 2020 revenue that were of $6.01 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2022 (TTM) | $94.31 M | 123% |
2021 | $42.29 M | 602.69% |
2020 | $6.01 M | -79.1% |
2019 | $28.79 M | 432.35% |
2018 | $5.4 M | -28.63% |
2017 | $7.57 M | 201.35% |
2016 | $2.51 M | -86.78% |
2015 | $19.02 M | 4.97% |
2014 | $18.12 M | 1301.7% |
2013 | $1.29 M | -93.3% |
2012 | $19.28 M | -88.3% |
2011 | $0.16 B | 268.94% |
2010 | $44.68 M | 115.66% |
2009 | $20.71 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | $34.12 B | 36,079.45% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 29,787.93% | ๐บ๐ธ USA |
Biogen BIIB | $9.83 B | 10,328.02% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $13.11 B | 13,807.27% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | 47,616.79% | ๐บ๐ธ USA |
Merrimack Pharmaceuticals MACK | N/A | N/A | ๐บ๐ธ USA |